Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nemtabrutinib + Lisocabtagene Maraleucel in Relapsed/Refractory CLL/SLL
NCT07194980Phase 2Recruiting
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Dec 2026
- Primary completion
- Oct 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nemtabrutinib in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by Fred Hutchinson Cancer Center. Planned start Dec 2026; status: recruiting.
02
Drugs
nemtabrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT07194980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07194980.